Yes. As a result of the merger, each Celgene common share (other than shares held by stockholders who validly perfect appraisal rights under Delaware law), was automatically canceled and converted into the right to receive the Merger Consideration:
1 share of Bristol-Myers Squibb common stock (NYSE: BMY)
$50 cash
1 CVR (NYSE: BMYRT)
The Celgene shares were delisted from the NASDAQ stock exchange and are no longer trading.